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The P-value has no relation to the severity of 
effectiveness. P-value represents only the odds of 
observed correlation. So, for example, when its value 
equals to 0.0001, indicates that 0.0001 is the 
probability of  observed association might has been 
due to odds; and compared with P-value = 0.01, it 
doesn’t indicate greater severity of association. In the 
studies that evaluate effectiveness of an intervention 
compared to placebo about binary outcomes, three 
indices: Absolute Risk Reduction (ARR), Relative 
Risk Reduction (RRR), and Number Needed to Treat 
(NNT) -to avoid a bad outcome- are indicating 
indices of the effectiveness and benefits of treatment. 
To understand these concepts, let us assume that an 
article from a randomized controlled clinical trial on 
the efficacy of the drug “Y” we have in hand. In this 
article is mentioned that among the 8000 patients 
with hypertension treated with the drug “X”, 120 
cases would experienced myocardial infarction (MI) 
after five years, and among 4000 patients treated 
with the drug “Y”, 30 cases of MI would have 
occurred; In the control group were treated with 
placebo, 150 MI occurred among 8000 cases. RRR 
indicates risk reduction ratio of unfortunate outcomes  
(here: the risk of MI) in the intervention group versus 
the control group. To calculate it, difference in MI 
risk in the intervention group and the control group 
will be divided into the risk of MIs.  
In the above example, the RRR is calculated as Table 
1. 
RRR states that Drug “X” reduces the risk of MI by 
20% compared to the control group. And 
administration of drug “Y” reduces this risk by 60% 
compared to the control group. A major imperfection 
of RRR is that cannot show outcome risk in the 
untreated group (control group) - the basic danger or 
CER. So it can not differentiate between effect sizes of 
large amount and small amount.  
In contrast, ARR that calculated by subtracting the 
outcome risk in the control group and intervention 
group, clearly demonstrates the difference between 
these states when the baseline risk is high or low. So, 
it keeps the impact of baseline risk of outcome. For 
example, for the drug “X” and “Y”, ARR is calculated 
as table 2. 
ARR is more meaningful and suitable indicator to 
measure the effect size than the RRR. 
On the other hand, to memorize the ARR and what it 
means for all treatment conditions and the work isn’t 
very simple; therefore, a quantity called the NNT is 
defined. It is calculated as 1 diveded by ARR. In fact, 
NNT tells us that how many patients should be treated 
with an intended intervention to prevent occurrence of 
the one unfortunate outcome. RRR and ARR and NNT 
values for the above example are in the table 3. 
The 267 patients with hypertension should be treated 
with drug “X” for 5 years to be prevented of one MI; 
Table 1:  
Risk  in control group Risk in exposure group RRR=  (CER –EER)/CER 
 
150/8000 =1.875% 
X Y X Y 
120/8000 = 1.5% 30/4000 = 0.75% 0.375/1.875 = 20% 1.8/1.875 = 60% 
EER: Experimental Event Rate   CER: Control Event Rate 
 
Table 2:  
Risk  in control group Risk in exposure group ARR=  (CER –EER) 
 
150/8000 =1.875% 
X Y X Y 
120/8000 = 1.5% 30/4000 = 0.75% 1.875-1.5 = 0.375% 1.875-0.75 = 1.125% 
 Table 3:  
Risk in exposure group Risk  in control group RRR ARR NNT 
X Y  
75/4000 =1.875% 
X Y X Y X Y 





Peg-Interferon Alfa 2-b Related Cellulitis in a 40 Years Man                                                                           Sali et al. 
NBM 189 Novelty in Biomedicine 2017, 4, 188-9 
nevertheless, it is 89 patients about drug “Y”. This 
indicates greater effectiveness of drug “Y” than “X”.  
So, NNT is the most appropriate index to determine 
the effectiveness of an intervention. 
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